• Enabling the possibility for a universal
    bone marrow transplant solution for patients
    with cancers and rare genetic diseases

  • Pioneering
    Science

  • Novel cellular and
    immune therapeutics

Latest Updates

Spotlight
18
Jun 2018
Jun 18, 2018

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Read More >
6
Aug 2018
Aug 6, 2018

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Read More >
23
Jul 2018
Jul 23, 2018

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Read More >
17
Jul 2018
Jul 17, 2018

Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation

Read More >

Gamida Cell is committed to changing the treatment paradigm for patients with cancer and rare genetic diseases.

One Technology:
Many Applications

Gamida Cell’s world-class scientists have developed a technology that offers the potential of curative cellular and immune therapeutics for a diverse population of patients in need. The proprietary NAM technology, which harnesses epigenetics to increase the population of functional cells in culture, is utilized to develop a broad pipeline of best-in-class therapies to treat cancer and rare genetic diseases.

Innovative Treatments

  • NiCord®

    NiCord®

    A Curative Treatment for High-Risk Blood Cancers

  • CordIn™

    CordIn™

    A Curative Treatment for Rare Genetic Diseases

  • NAM-NK Cells

    NAM-NK Cells

    An immunotherapy for Blood Cancers and Solid Tumors